Financhill
Sell
47

HQY Quote, Financials, Valuation and Earnings

Last price:
$86.97
Seasonality move :
14.43%
Day range:
$86.19 - $88.40
52-week range:
$65.01 - $115.59
Dividend yield:
0%
P/E ratio:
79.78x
P/S ratio:
6.43x
P/B ratio:
3.56x
Volume:
1.2M
Avg. volume:
1.2M
1-year change:
6.53%
Market cap:
$7.5B
Revenue:
$1.2B
EPS (TTM):
$1.09

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HQY
HealthEquity
$305.8M $0.72 12.21% 147.57% $112.36
ACCD
Accolade
$142.3M $0.19 14.34% -42.86% $7.03
HSTM
HealthStream
$73.5M $0.14 2.98% -- $35.00
SDGR
Schrodinger
$83.2M -$0.38 49.19% -6.58% $30.80
SLP
Simulations Plus
$21.9M $0.26 19.77% 31.43% $49.40
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HQY
HealthEquity
$86.96 $112.36 $7.5B 79.78x $0.00 0% 6.43x
ACCD
Accolade
$6.99 $7.03 $570.9M -- $0.00 0% 1.23x
HSTM
HealthStream
$32.03 $35.00 $974.8M 48.53x $0.03 0.36% 3.35x
SDGR
Schrodinger
$19.96 $30.80 $1.5B -- $0.00 0% 6.99x
SLP
Simulations Plus
$24.29 $49.40 $488M 60.73x $0.06 0.99% 6.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HQY
HealthEquity
33.31% 1.611 11.05% 2.65x
ACCD
Accolade
40.09% 3.274 66.82% 2.47x
HSTM
HealthStream
-- 0.998 -- 1.15x
SDGR
Schrodinger
-- 2.446 -- 3.17x
SLP
Simulations Plus
-- 1.776 -- 3.18x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HQY
HealthEquity
$189M $44.3M 3.11% 4.59% 14.5% $62.2M
ACCD
Accolade
$46.5M -$25.9M -29.12% -43.94% -24.61% -$10.6M
HSTM
HealthStream
$49.1M $4.7M 5.72% 5.72% 6.32% $4.3M
SDGR
Schrodinger
$64.1M -$20.7M -38.87% -38.87% -23.45% -$32M
SLP
Simulations Plus
$10.2M $126K 4.58% 4.58% 0.67% -$2.2M

HealthEquity vs. Competitors

  • Which has Higher Returns HQY or ACCD?

    Accolade has a net margin of 8.46% compared to HealthEquity's net margin of -115.42%. HealthEquity's return on equity of 4.59% beat Accolade's return on equity of -43.94%.

    Company Gross Margin Earnings Per Share Invested Capital
    HQY
    HealthEquity
    60.63% $0.30 $3.2B
    ACCD
    Accolade
    44.25% -$1.50 $522.4M
  • What do Analysts Say About HQY or ACCD?

    HealthEquity has a consensus price target of $112.36, signalling upside risk potential of 29.21%. On the other hand Accolade has an analysts' consensus of $7.03 which suggests that it could grow by 0.51%. Given that HealthEquity has higher upside potential than Accolade, analysts believe HealthEquity is more attractive than Accolade.

    Company Buy Ratings Hold Ratings Sell Ratings
    HQY
    HealthEquity
    9 1 0
    ACCD
    Accolade
    0 11 0
  • Is HQY or ACCD More Risky?

    HealthEquity has a beta of 0.617, which suggesting that the stock is 38.323% less volatile than S&P 500. In comparison Accolade has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HQY or ACCD?

    HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accolade offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HealthEquity pays -- of its earnings as a dividend. Accolade pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HQY or ACCD?

    HealthEquity quarterly revenues are $311.8M, which are larger than Accolade quarterly revenues of $105.1M. HealthEquity's net income of $26.4M is higher than Accolade's net income of -$121.3M. Notably, HealthEquity's price-to-earnings ratio is 79.78x while Accolade's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 6.43x versus 1.23x for Accolade. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HQY
    HealthEquity
    6.43x 79.78x $311.8M $26.4M
    ACCD
    Accolade
    1.23x -- $105.1M -$121.3M
  • Which has Higher Returns HQY or HSTM?

    HealthStream has a net margin of 8.46% compared to HealthEquity's net margin of 6.59%. HealthEquity's return on equity of 4.59% beat HealthStream's return on equity of 5.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    HQY
    HealthEquity
    60.63% $0.30 $3.2B
    HSTM
    HealthStream
    66.17% $0.16 $359.4M
  • What do Analysts Say About HQY or HSTM?

    HealthEquity has a consensus price target of $112.36, signalling upside risk potential of 29.21%. On the other hand HealthStream has an analysts' consensus of $35.00 which suggests that it could grow by 9.27%. Given that HealthEquity has higher upside potential than HealthStream, analysts believe HealthEquity is more attractive than HealthStream.

    Company Buy Ratings Hold Ratings Sell Ratings
    HQY
    HealthEquity
    9 1 0
    HSTM
    HealthStream
    2 4 0
  • Is HQY or HSTM More Risky?

    HealthEquity has a beta of 0.617, which suggesting that the stock is 38.323% less volatile than S&P 500. In comparison HealthStream has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.556%.

  • Which is a Better Dividend Stock HQY or HSTM?

    HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HealthStream offers a yield of 0.36% to investors and pays a quarterly dividend of $0.03 per share. HealthEquity pays -- of its earnings as a dividend. HealthStream pays out 17.01% of its earnings as a dividend. HealthStream's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HQY or HSTM?

    HealthEquity quarterly revenues are $311.8M, which are larger than HealthStream quarterly revenues of $74.2M. HealthEquity's net income of $26.4M is higher than HealthStream's net income of $4.9M. Notably, HealthEquity's price-to-earnings ratio is 79.78x while HealthStream's PE ratio is 48.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 6.43x versus 3.35x for HealthStream. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HQY
    HealthEquity
    6.43x 79.78x $311.8M $26.4M
    HSTM
    HealthStream
    3.35x 48.53x $74.2M $4.9M
  • Which has Higher Returns HQY or SDGR?

    Schrodinger has a net margin of 8.46% compared to HealthEquity's net margin of -45.54%. HealthEquity's return on equity of 4.59% beat Schrodinger's return on equity of -38.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    HQY
    HealthEquity
    60.63% $0.30 $3.2B
    SDGR
    Schrodinger
    72.61% -$0.55 $421.4M
  • What do Analysts Say About HQY or SDGR?

    HealthEquity has a consensus price target of $112.36, signalling upside risk potential of 29.21%. On the other hand Schrodinger has an analysts' consensus of $30.80 which suggests that it could grow by 54.31%. Given that Schrodinger has higher upside potential than HealthEquity, analysts believe Schrodinger is more attractive than HealthEquity.

    Company Buy Ratings Hold Ratings Sell Ratings
    HQY
    HealthEquity
    9 1 0
    SDGR
    Schrodinger
    6 3 0
  • Is HQY or SDGR More Risky?

    HealthEquity has a beta of 0.617, which suggesting that the stock is 38.323% less volatile than S&P 500. In comparison Schrodinger has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.426%.

  • Which is a Better Dividend Stock HQY or SDGR?

    HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Schrodinger offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HealthEquity pays -- of its earnings as a dividend. Schrodinger pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HQY or SDGR?

    HealthEquity quarterly revenues are $311.8M, which are larger than Schrodinger quarterly revenues of $88.3M. HealthEquity's net income of $26.4M is higher than Schrodinger's net income of -$40.2M. Notably, HealthEquity's price-to-earnings ratio is 79.78x while Schrodinger's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 6.43x versus 6.99x for Schrodinger. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HQY
    HealthEquity
    6.43x 79.78x $311.8M $26.4M
    SDGR
    Schrodinger
    6.99x -- $88.3M -$40.2M
  • Which has Higher Returns HQY or SLP?

    Simulations Plus has a net margin of 8.46% compared to HealthEquity's net margin of 1.09%. HealthEquity's return on equity of 4.59% beat Simulations Plus's return on equity of 4.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    HQY
    HealthEquity
    60.63% $0.30 $3.2B
    SLP
    Simulations Plus
    54% $0.01 $184.7M
  • What do Analysts Say About HQY or SLP?

    HealthEquity has a consensus price target of $112.36, signalling upside risk potential of 29.21%. On the other hand Simulations Plus has an analysts' consensus of $49.40 which suggests that it could grow by 103.38%. Given that Simulations Plus has higher upside potential than HealthEquity, analysts believe Simulations Plus is more attractive than HealthEquity.

    Company Buy Ratings Hold Ratings Sell Ratings
    HQY
    HealthEquity
    9 1 0
    SLP
    Simulations Plus
    6 1 0
  • Is HQY or SLP More Risky?

    HealthEquity has a beta of 0.617, which suggesting that the stock is 38.323% less volatile than S&P 500. In comparison Simulations Plus has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.602%.

  • Which is a Better Dividend Stock HQY or SLP?

    HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Simulations Plus offers a yield of 0.99% to investors and pays a quarterly dividend of $0.06 per share. HealthEquity pays -- of its earnings as a dividend. Simulations Plus pays out 48.18% of its earnings as a dividend. Simulations Plus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HQY or SLP?

    HealthEquity quarterly revenues are $311.8M, which are larger than Simulations Plus quarterly revenues of $18.9M. HealthEquity's net income of $26.4M is higher than Simulations Plus's net income of $206K. Notably, HealthEquity's price-to-earnings ratio is 79.78x while Simulations Plus's PE ratio is 60.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 6.43x versus 6.63x for Simulations Plus. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HQY
    HealthEquity
    6.43x 79.78x $311.8M $26.4M
    SLP
    Simulations Plus
    6.63x 60.73x $18.9M $206K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will SoundHound AI Stock Recover?
Will SoundHound AI Stock Recover?

SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…

What Stocks Did Warren Buffett Just Buy?
What Stocks Did Warren Buffett Just Buy?

In Q4 of last year, Warren Buffett added to or…

Is it Finally Time to Buy Medical Properties Trust?
Is it Finally Time to Buy Medical Properties Trust?

Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 36x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Sell
41
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 37x

Alerts

Buy
78
AJINY alert for Mar 29

Ajinomoto [AJINY] is up 99.61% over the past day.

Buy
69
AGX alert for Mar 29

Argan [AGX] is up 19.83% over the past day.

Sell
24
AIR alert for Mar 29

AAR [AIR] is down 16.36% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock